Could your own immune cells beat advanced melanoma?
NCT ID NCT06120712
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This trial tested a new treatment called GC101 TIL for people with advanced melanoma that has not responded to standard therapies. The treatment uses immune cells taken from the patient's own tumor, grown in a lab, and then given back to the patient. The study enrolled 18 participants and looked at safety and whether the tumors shrank.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
GC101 TIL (tumor-infiltrating lymphocytes, a type of immune cell taken from the patient's own tumor)
What this could lead to
If it works, this could point toward a new treatment option for people with advanced melanoma who have run out of standard therapies.
What could go wrong
This is an early-phase trial with only 18 participants, so results may not apply to everyone. The treatment involves serious side effects and may not shrink tumors in all patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MELANOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Beijing Cancer Hospital
Beijing, China